1
|
Battisti NML, Sehovic M, Extermann M. Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non–Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older. Clin Lung Cancer 2017; 18:460-471. [DOI: 10.1016/j.cllc.2017.03.005] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2016] [Revised: 03/04/2017] [Accepted: 03/06/2017] [Indexed: 12/25/2022]
|
2
|
Nagy Á, Pongor LS, Szabó A, Santarpia M, Győrffy B. KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer. Int J Cancer 2016; 140:930-937. [PMID: 27859136 PMCID: PMC5299512 DOI: 10.1002/ijc.30509] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2016] [Revised: 10/22/2016] [Accepted: 10/28/2016] [Indexed: 01/22/2023]
Abstract
KRAS is the most frequently mutated oncogene in non‐small cell lung cancer (NSCLC). However, the prognostic role of KRAS mutation status in NSCLC still remains controversial. We hypothesize that the expression changes of genes affected by KRAS mutation status will have the most prominent effect and could be used as a prognostic signature in lung cancer. We divided NSCLC patients with mutation and RNA‐seq data into KRAS mutated and wild type groups. Mann‐Whitney test was used to identify genes showing altered expression between these cohorts. Mean expression of the top five genes was designated as a “transcriptomic fingerprint” of the mutation. We evaluated the effect of this signature on clinical outcome in 2,437 NSCLC patients using univariate and multivariate Cox regression analysis. Mutation of KRAS was most common in adenocarcinoma. Mutation status and KRAS expression were not correlated to prognosis. The transcriptomic fingerprint of KRAS include FOXRED2, KRAS, TOP1, PEX3 and ABL2. The KRAS signature had a high prognostic power. Similar results were achieved when using the second and third set of strongest genes. Moreover, all cutoff values delivered significant prognostic power (p < 0.01). The KRAS signature also remained significant (p < 0.01) in a multivariate analysis including age, gender, smoking history and tumor stage. We generated a “surrogate signature” of KRAS mutation status in NSCLC patients by computationally linking genotype and gene expression. We show that secondary effects of a mutation can have a higher prognostic relevance than the primary genetic alteration itself. What's new? As many as one‐quarter of patients with lung adenocarcinoma (AC), a form of non‐small cell lung cancer (NSCLC), exhibit tumor‐associated mutations in KRAS. Whether KRAS mutation status and expression are correlated to prognosis, however, remains unclear. In this study, a surrogate signature of KRAS mutation status was generated for NSCLC by relating genotype to gene‐expression signature. The approach led to the identification of a significant correlation between overall survival in lung AC and the transcriptomic fingerprint of somatic KRAS mutations. Three genes strongly influenced by KRAS mutation may be relevant to the search for novel NSCLC drug targets.
Collapse
Affiliation(s)
- Ádám Nagy
- MTA TTK Lendület Cancer Biomarker Research Group, Budapest, Magyar, Hungary.,Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary
| | - Lőrinc Sándor Pongor
- MTA TTK Lendület Cancer Biomarker Research Group, Budapest, Magyar, Hungary.,Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary
| | - András Szabó
- Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary
| | - Mariacarmela Santarpia
- Medical Oncology Unit, Department of Human Pathology 'G. Barresi', University of Messina, Italy
| | - Balázs Győrffy
- MTA TTK Lendület Cancer Biomarker Research Group, Budapest, Magyar, Hungary.,Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary
| |
Collapse
|
3
|
|
4
|
The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). Tumour Biol 2014; 36:2491-9. [PMID: 25417899 DOI: 10.1007/s13277-014-2862-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Accepted: 11/14/2014] [Indexed: 10/24/2022] Open
Abstract
Bevacizumab (Bev), a monoclonal antibody against vascular endothelial growth factor, when combined with standard first-line chemotherapy, shows impressive clinical benefit in advanced non-squamous non-small cell lung cancer (ns-NSCLC). Our study aims to investigate whether the addition of Bev to pemetrexed improves progression-free survival (PFS) in advanced ns-NSCLC patients after the failure of at least one prior chemotherapy regimens. Patients with locally advanced, recurrent, or metastatic ns-NSCLC, after failure of platinum-based therapy, with a performance status 0 to 2, were eligible. Patients received 500 mg/m(2) of pemetrexed intravenously (IV) day 1 with vitamin B12, folic acid, and dexamethasone and Bev 7.5 mg/kg IV day 1 of a 21-day cycle until unacceptable toxicity, disease progression or the patient requested therapy discontinuation. The primary end point was PFS. Between December 2011 and October 2013, 33 patients were enrolled, with median age of 55 years and 36.4% men. Twenty-three patients (69.7%) had received two or more prior regimens, and 28 patients (84.8%) had received chemotherapy containing pemetrexed. The median number of the protocol regimens was 4. Median PFS was 4.37 months (95% CI 2.64-6.09 months). Median overall survival (OS) was 15.83 months (95% CI 10.52-21.15 months). Overall response rates were 6.45%. Disease control rate was 54.84%. No new safety signals were detected. No patient experienced drug-related deaths. The combination of Bev and pemetrexed every 21 days is effective in ns-NSCLC patients who failed of prior therapies with improved PFS. Toxicities are similar with historical data of these two agents and are tolerable. Our results may provide more a regimen containing Bev and pemetrexed for Chinese clinical practice in previously treated ns-NSCLC.
Collapse
|
5
|
Dooms CA, Pat KE, Vansteenkiste JF. The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. Expert Rev Anticancer Ther 2014; 6:531-44. [PMID: 16613541 DOI: 10.1586/14737140.6.4.531] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Differences in survival outcomes with various treatments for advanced non-small cell lung cancer are very modest. Despite this, end points looking at the patients' subjective benefit, such as symptom control, quality of life or clinical benefit, have only been sparsely implemented into clinical trials as primary points of interest. This review focuses on available evidence regarding these patients' subjective end points in recent clinical trials. Compared with best supportive care, chemotherapy offers symptom control, not only in patients with objective response to chemotherapy, but also in a proportion of patients with disease stabilization. However, interpretation of quality-of-life objectives is more difficult, owing to several methodological problems, but improvement in various domains of quality of life is also reported. Different treatment options, such as older platinum-based schedules, modern platinum-based doublets, single-agent treatment with a new drug or nonplatinum-based doublets, are comprehensively reviewed. Future randomized studies should take up the challenge of looking at the patients' benefit as a primary end point.
Collapse
Affiliation(s)
- Christophe A Dooms
- University Hospital Gasthuisberg, Respiratory Oncology Unit, Dept of Pulmonology, Herestraat 49, B-3000 Leuven, Belgium
| | | | | |
Collapse
|
6
|
Abstract
Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with locally advanced or metastatic disease. In this setting the goal of treatment is to prolong survival and to control disease- and treatment-related symptoms. Currently systemic cytotoxic chemotherapy remains the first-line treatment for most patients with stage IV NSCLC, but preferred treatments are now defined by histology and based on the presence of specific molecular abnormalities. In first-line the combination of platinum plus pemetrexed with or without bevacizumab is a reasonable choice in patients with non-squamous NSCLC. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy are the recommended for patients with EGFR-sensitizing mutations. A small-molecule TKI of anaplastic lymphoma kinase (ALK), crizotinib, showed pronounced clinical activity in the treatment of patients with NSCLC positive for EML4-ALK and it has rapidly entered into daily clinical practice. Currently no agents are specifically approved for the treatment of squamous cell carcinoma of the lung. Second-line treatments include docetaxel, pemetrexed, or erlotinib as single agents. There is a growing evidence that cytotoxics are better than EGFR-TKIs in EGFR wild-type patients. In the setting of the third line, the only approved agent is erlotinib. In elderly patients with good performance status (PS), doublet chemotherapy including platinum should not be excluded, especially for those patients 70-75 years of age without comorbidities. The better selection of patients, the identification of specific predictive biomarkers, a reasonable sequencing of all active and available treatments, including targeted therapies and cytotoxic, may significantly contribute to extend the natural history of stage IV NSCLC.
Collapse
|
7
|
Baykara M, Coskun U, Berk V, Ozkan M, Kaplan MA, Benekli M, Karaca H, Inanc M, Isikdogan A, Sevinc A, Elkiran ET, Demirci U, Buyukberber S. Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2013; 13:5119-24. [PMID: 23244121 DOI: 10.7314/apjcp.2012.13.10.5119] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
PURPOSE The aim of this retrospective study was to determine response rates, progression-free survival (PFS), overall survival (OS) and toxicity of gemcitabine and paclitaxel combinations with advanced or metastatic non-small cell lung cancer patients (NSCLC) who have progressive disease after platinum-based first-line chemotherapy. METHODS We retrospectively evaluated the file records of patients treated with gemcitabine plus paclitaxel in advanced or metastatic NSCLC cases in a second-line setting. The chemotherapy schedule was as follows: gemcitabine 1500 mg/m2 and paclitaxel 150 mg/m2 administered every two weeks. RESULTS Forty-eight patients (45 male, 3 female) were evaluated; stage IIIB/IV 6/42; PS0, 8.3%, PS1, 72.9%, PS2, 18.8%; median age, 56 years old (range 38-76). Six (12.5%) patients showed a partial response (PR), 13 (27.1%) stable disease (SD), and 27 (56.3%) progressive disease (PD). The median OS was 6.63 months (95% CI 4.0-9.2); the median PFS was 2.7 months (95% CI 1.8-3.6). Grade 3 and 4 hematologic toxicities, including neutropenia (n=4, 8.4%), and anemia (n=3, 6.3%) were encountered, but no grade 3 or 4 thrombocytopenia. One patient developed febrile neutropenia. There were no interruption for reasons of toxicity and no exitus related to therapy. CONCLUSION The combination of two-weekly gemcitabine plus paclitaxel was an effective and well-tolerated second-line chemotherapy regimen for advanced or metastatic NSCLC patients previously treated with platinum-containing chemotherapy. Although the most common and dose limiting toxicities were neutropenia and neuropathy, this regimen was tolerated well by the patients.
Collapse
Affiliation(s)
- Meltem Baykara
- Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya, Turkey.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial. J Clin Oncol 2012; 30:4501-7. [DOI: 10.1200/jco.2012.43.6758] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Purpose To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). Primary end point was progression-free survival (PFS). A preplanned pooled analysis of the results of this study with those of the NVALT7 study was carried out to assess the impact of carboplatin added to pemetrexed in terms of overall survival (OS). Results From July 2007 to October 2009, 239 patients (arm A, n = 120; arm B, n = 119) were enrolled. Median PFS was 3.6 months for arm A versus 3.5 months for arm B (hazard ratio [HR], 1.05; 95% CI, 0.81 to 1.36; P = .706). No statistically significant differences in response rate, OS, or toxicity were observed. A total of 479 patients were included in the pooled analysis. OS was not improved by the addition of carboplatin to pemetrexed (HR, 90; 95% CI, 0.74 to 1.10; P = .316; P heterogeneity = .495). In the subgroup analyses, the addition of carboplatin to pemetrexed in patients with squamous tumors led to a statistically significant improvement in OS from 5.4 to 9 months (adjusted HR, 0.58; 95% CI, 0.37 to 0.91; P interaction test = .039). Conclusion Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. The benefit observed with carboplatin addition in squamous tumors may warrant further investigation.
Collapse
Affiliation(s)
- Andrea Ardizzoni
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Marcello Tiseo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Luca Boni
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Andrew D. Vincent
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Rodolfo Passalacqua
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Sebastiano Buti
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Domenico Amoroso
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Andrea Camerini
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Roberto Labianca
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Giovenzio Genestreti
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Corrado Boni
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Libero Ciuffreda
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Francesco Di Costanzo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Filippo de Marinis
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Lucio Crinò
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Antonio Santo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Antonio Pazzola
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Fausto Barbieri
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Nicoletta Zilembo
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Ida Colantonio
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Carmelo Tibaldi
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Rodolfo Mattioli
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Mara A. Cafferata
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Roberta Camisa
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| | - Egbert F. Smit
- Andrea Ardizzoni, Marcello Tiseo, and Roberta Camisa, Azienda Ospedaliero-Universitaria, Parma; Luca Boni and Francesco Di Costanzo, Azienda Ospedaliero-Universitaria Careggi, Firenze; Rodolfo Passalacqua and Sebastiano Buti, Ospedale Civile, Cremona; Domenico Amoroso and Andrea Camerini, Ospedale della Versilia, Lido di Camaiore; Roberto Labianca, Ospedali Riuniti, Bergamo; Giovenzio Genestreti, Istituto Oncologico Romagnolo, Meldola; Corrado Boni, Ospedale Santa Maria Nuova, Reggio Emilia; Libero
| |
Collapse
|
9
|
Matsubara N, Maemondo M, Inoue A, Ishimoto O, Watanabe K, Sakakibara T, Fukuhara T, Morikawa N, Tanaka M, Sugawara S, Nukiwa T. Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703. Respir Investig 2012; 51:28-34. [PMID: 23561256 DOI: 10.1016/j.resinv.2012.09.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2012] [Revised: 08/31/2012] [Accepted: 09/04/2012] [Indexed: 11/29/2022]
Abstract
BACKGROUND We aimed to evaluate the efficacy and safety of irinotecan monotherapy as a third- or fourth-line treatment for advanced non-small cell lung cancer (NSCLC) patients. METHODS Patients with advanced NSCLC refractory to 2 or more previous regimens were treated with 80 mg/m2 irinotecan on days 1, 8, and 15, every 4 weeks. The primary endpoint was the overall response rate (ORR), whereas secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity profiles. RESULTS From December 2007 to April 2009, 32 patients (median age, 60 years) were enrolled. Most of the patients (75.0%) were male, and 18.8% had a performance status of 2. Six partial responses to irinotecan monotherapy were observed (ORR, 18.8%: 95% confidence interval, 5.3%-32.3%). The disease control rate (DCR) was 78.1%, median PFS was 4.0 months, and median survival time (MST) was 10.4 months. Grade 3-4 neutropenia was observed in 22% of patients, but other toxic effects were moderate. No cases of grade 3-4 diarrhea or treatment-related death were noted. Of the 15 patients for whom progressive disease represented the best response to previous treatment regimens, 2 exhibited a partial response and 9 showed stable disease after irinotecan monotherapy, with a DCR of 73.3%, median PFS of 4.4 months, and MST of 8.2 months. CONCLUSIONS Irinotecan monotherapy is effective for advanced NSCLC patients who have previously failed 2 or more treatment regimens.
Collapse
Affiliation(s)
- Nobumichi Matsubara
- Department of Respiratory Medicine, Miyagi Cancer Center, 47-1 Nodayama, Medeshima-shiote, Natori, 981-1293, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Factors Affecting Efficacy and Safety of Add-On Combination Chemotherapy for Non-Small-Cell Lung Cancer: A Literature-Based Pooled Analysis of Randomized Controlled Trials. Lung 2012; 190:355-64. [DOI: 10.1007/s00408-012-9379-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2011] [Accepted: 01/22/2012] [Indexed: 10/28/2022]
|
11
|
de Marinis F, Ricciardi S. Second-line treatment options in advanced non-small cell lung cancer. Eur J Cancer 2011; 47 Suppl 3:S258-71. [DOI: 10.1016/s0959-8049(11)70172-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
12
|
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 2011; 73:1-10. [DOI: 10.1016/j.lungcan.2011.02.022] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2011] [Revised: 02/18/2011] [Accepted: 02/27/2011] [Indexed: 11/22/2022]
|
13
|
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study. Am J Clin Oncol 2011; 34:38-42. [PMID: 20142722 DOI: 10.1097/coc.0b013e3181cae90e] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE The combinations of cisplatin-pemetrexed and cisplatin-gemcitabine are considered the standard systemic therapy for malignant pleural mesothelioma (MPM), which is a rapidly progressive tumor. The purpose of the present study is to evaluate the efficacy, safety, and clinical benefit of the gemcitabine plus docetaxel regimen in the second-line treatment of this disease. PATIENTS AND METHODS A total of 37 patients with MPM were treated with the combination of docetaxel (80 mg/m) and gemcitabine (1000 mg/m) on day 1 and 14 of a 28-day cycle. The regimen was repeated for a maximum of 6 cycles or until disease progression or unacceptable toxicity. RESULTS There was partial response of the disease in 7 patients (18.9%), whereas it remained stable in 23 patients (62.2%) and progressed in 7 patients (18.9%). The median time to disease progression was 7 months (range: 5.8-8.2 months) with a mean survival of 16.2 months (range: 13-19.3 months). CONCLUSION The biweekly administration of docetaxel and gemcitabine, along with granulocyte colony-stimulating factor support, constitutes a safe, tolerable, and convenient regimen for the treatment of MPM, suggesting that this combination may be a viable option, especially in previously treated patients.
Collapse
|
14
|
Pallis AG, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N, Pavlakou G, Kotsakis A, Kontopodis E, Georgoulias V. A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. BMC Cancer 2010; 10:633. [PMID: 21092076 PMCID: PMC2994826 DOI: 10.1186/1471-2407-10-633] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2010] [Accepted: 11/19/2010] [Indexed: 11/20/2022] Open
Abstract
Background To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel (D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC). Methods Patients pre-treated with front-line platinum-free regimens, were randomized to receive either docetaxel/carboplatin (DC), (docetaxel 50 mg/m2; carboplatin AUC4; both drugs administered on days 1 and 15) or docetaxel single-agent (D), (docetaxel 50 mg/m2 on days 1 and 15). Results Response rate was similar between the two arms (DC vs D: 10.4% vs 7.7%; p = 0.764). After a median follow-up time of 28.0 months for DC arm and 34.5 months for D arm, progression free survival (PFS) was significantly higher in the DC arm (DC vs D:3.33 months vs 2.60 months; p-value = 0.012), while no significant difference was observed in terms of overall survival (OS) (DC vs D: 10.3 months vs 7.70 months; p-value = 0.550). Chemotherapy was well-tolerated and grade III/IV toxicities were relatively infrequent. No toxic deaths were observed. Conclusions This study has not achieved its primary objective of significant OS prolongation with docetaxel/carboplatin combination over single-agent docetaxel in patients who had not received front-line docetaxel; however, the docetaxel/carboplatin combination was associated with a significant clinical benefit in terms of PFS.
Collapse
|
15
|
Caponi S, Vasile E, Ginocchi L, Tibaldi C, Borghi F, D’Incecco A, Lucchesi M, Caparello C, Andreuccetti M, Falconel A. Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All. Clin Lung Cancer 2010; 11:320-7. [DOI: 10.3816/clc.2010.n.040] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
16
|
Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, Tsai CM, Camps C, Schuette W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli C. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. Eur J Cancer 2010; 46:735-43. [DOI: 10.1016/j.ejca.2009.12.013] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2009] [Revised: 12/01/2009] [Accepted: 12/03/2009] [Indexed: 10/20/2022]
|
17
|
Second and third line treatment in non-small cell lung cancer. Crit Rev Oncol Hematol 2009; 71:117-26. [DOI: 10.1016/j.critrevonc.2009.01.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2008] [Revised: 01/28/2009] [Accepted: 01/29/2009] [Indexed: 01/11/2023] Open
|
18
|
Oizumi S, Yamazaki K, Yokouchi H, Konishi J, Hommura F, Kojima T, Isobe H, Nishimura M. Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy. Int J Clin Oncol 2009; 14:125-9. [PMID: 19390943 DOI: 10.1007/s10147-008-0808-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2007] [Accepted: 06/11/2008] [Indexed: 11/29/2022]
Abstract
BACKGROUND Combination chemotherapy comprising amrubicin and vinorelbine as a second-line therapy for advanced non-small cell lung cancer (NSCLC) has not been fully evaluated. To determine the maximum tolerated dose (MTD) and recommended dose (RD), the present phase I study examined patients with advanced NSCLC. METHODS The subjects were nine patients with histologically confirmed advanced NSCLC, Eastern Cooperative Oncology Group performance status 0-1, prior platinum-based first-line chemotherapy, and measurable or evaluable lesions. Treatment consisted of five dose levels, with amrubicin 35-45 mg/m2 administered as a 5-min intravenous infusion on days 1-3 and vinorelbine 15-25 mg/m2 given as a 1-h intravenous infusion on days 1 and 8, every 3 weeks. RESULTS All patients had received carboplatin and paclitaxel as first-line therapy. Dose-limiting toxicity (DLT) was seen in two of six patients (febrile neutropenia and deep vein thrombosis ) at level 1, allowing us to conduct level 2. At level 2, all three patients experienced DLT (leucopenia > or =4 days in one patient; febrile neutropenia in three patients; and infection in two patients), and this level was determined as the MTD. Subsequently, level 1 (amrubicin 35 mg/m2 and vinorelbine 15 mg/m2) was defined as the RD. Responses in the nine patients included a partial response in one patient and stable disease in four patients. CONCLUSION As second-line therapy, the RD of the combination of amrubicin and vinorelbine is 35 mg/m2 and 15 mg/m2, respectively. Further study should proceed to clarify the efficacy of this regimen.
Collapse
Affiliation(s)
- Satoshi Oizumi
- First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C. Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer. J Clin Oncol 2009; 27:1836-43. [PMID: 19273711 DOI: 10.1200/jco.2008.17.5844] [Citation(s) in RCA: 133] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Doublet chemotherapy is more effective than single-agent as first-line treatment of advanced non–small-cell lung cancer (NSCLC). As second-line treatment, several randomized trials have been performed comparing single-agent with doublet chemotherapy, but each trial had an insufficient power to detect potentially relevant differences in survival. Methods We performed meta-analysis of individual patient data from randomized trials, both published and unpublished, comparing single-agent with doublet chemotherapy as second-line treatment of advanced NSCLC. Primary end point was overall survival (OS). All statistical analyses were stratified by trial. Results Eight eligible trials were identified. Data of two trials were not available, and data of six trials (847 patients) were collected. Median age was 61 years. Performance status was 0 or 1 in 90%; 80% of patients had received previous platin-based chemotherapy. OS was not significantly different between arms (P = .32). Median OS was 37.3 and 34.7 weeks in the doublet and single-agent arms, respectively. Hazard ratio (HR) was 0.92 (95% CI, 0.79 to 1.08). Response rate was 15.1% with doublet and 7.3% with single-agent (P = .0004). Median progression-free survival was 14 weeks for doublet and 11.7 weeks for single agent (P = .0009; HR, 0.79; 95% CI, 0.68 to 0.91). There was no significant heterogeneity among trials for the three efficacy outcomes. Patients treated with doublet chemotherapy had significantly more grade 3 to 4 hematologic (41% v 25%; P < .0001) and grade 3 to 4 nonhematologic toxicity (28% v 22%; P = .034). Conclusion Doublet chemotherapy as second-line treatment of advanced NSCLC significantly increases response rate and progression-free survival, but is more toxic and does not improve overall survival compared to single-agent.
Collapse
Affiliation(s)
- Massimo Di Maio
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Paolo Chiodini
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Vassilis Georgoulias
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Dora Hatzidaki
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Koji Takeda
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Floris M. Wachters
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Vittorio Gebbia
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Egbert F. Smit
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Alessandro Morabito
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Ciro Gallo
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Francesco Perrone
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| | - Cesare Gridelli
- From the Clinical Trials Unit, National Cancer Institute; Department of Medicine and Public Health, Second University of Napoli; Division of Medical Oncology, “N.Giannettasio” Hospital, Rossano; La Maddalena, University of Palermo; Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy; Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece; Osaka City General Hospital, Osaka, Japan; Department of Pulmonology, University Medical Center, Groningen; and
| |
Collapse
|
20
|
Gebbia V, Gridelli C, Verusio C, Frontini L, Aitini E, Daniele B, Gamucci T, Mancuso G, Di Maio M, Gallo C, Perrone F, Morabito A. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. Lung Cancer 2009; 63:251-8. [DOI: 10.1016/j.lungcan.2008.05.027] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2008] [Revised: 05/21/2008] [Accepted: 05/25/2008] [Indexed: 11/12/2022]
|
21
|
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol 2008; 64:79-86. [PMID: 18941749 DOI: 10.1007/s00280-008-0845-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2008] [Accepted: 09/23/2008] [Indexed: 10/21/2022]
Abstract
PURPOSE The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. METHODS Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). RESULTS Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 +/- 0.94 SD, vs 0.41 +/- 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 +/- 1.49 SD, vs 0.29 +/- 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). CONCLUSION RRM2 gene and protein expression varies by tumor type.
Collapse
|
22
|
Phase I/II Study of Docetaxel and S-1 in Patients with Previously Treated Non-small Cell Lung Cancer. J Thorac Oncol 2008; 3:1012-7. [PMID: 18758304 DOI: 10.1097/jto.0b013e318183f8ed] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
23
|
Gebbia V. Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer? Expert Opin Pharmacother 2008; 9:1321-37. [PMID: 18473707 DOI: 10.1517/14656566.9.8.1321] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND A growing percentage of patients affected by advanced non-small cell lung cancer who progressed after first-line chemotherapy still have a good performance status and require second-line treatment. OBJECTIVE An overview of the state of the art of second-line therapeutic options is presented. METHODS The scope of the review is to give an update on the therapeutic options currently available for the second-line treatment of patients with advanced non-small cell lung cancer. RESULTS AND CONCLUSIONS Among chemotherapeutic drugs docetaxel and pemetrexed have been approved for second-line treatment of advanced non-small cell lung cancer. Although the drugs are equiactive in terms of response rate and survival parameters the latter has a clear-cut advantage in terms of tolerability and quality of life. Therefore, pemetrexed is considered the best second-line therapeutic option in order to avoid severe side effects. Among biologic agents the tyrosine kinase inhibitors gefinitib and erlotinib have been largely tested, but only the latter has been approved for second- and third-line treatment. Erlotinib has been reported to be particularly active in patients with adenocarcinoma, in females, in patients of Asian ethnicity and in epidermal growth factor receptor mutations and it is also active in the third-line setting. At present, no direct head to head comparison of erlotinib with any chemotherapeutic agent has been performed. A rational decision tree may therefore include pemetrexed or docetaxel (the former preferred for tolerability) or erlotinib as standard second-line therapy. Erlotinib has been also shown to be active as third-line treatment: however, in cases of patients with clinical characteristics suggesting a good response to tyrosine kinase inhibitors, erlotinib may be employed in an earlier phase.
Collapse
Affiliation(s)
- Vittorio Gebbia
- Medical Oncology University of Palermo, Department of Experimental Oncology and Clinical Applications, Palermo, Italy.
| |
Collapse
|
24
|
Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum. J Thorac Oncol 2008; 3:637-42. [PMID: 18520804 DOI: 10.1097/jto.0b013e318174e070] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND An open-label, single-arm prospective study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine and tegafur-uracil (UFT) in patients with advanced nonsmall-cell lung cancer (NSCLC) after the failure of previous platinum-containing regimens. PATIENTS AND METHODS Patients with advanced NSCLC received 200 mg/m2 of UFT twice daily from day 1 through 14 plus 900 mg/m2 of gemcitabine per day via intravenous injection on days 8 and 15. This regimen was repeated every 3 or 4 weeks. RESULTS A total of 40 patients were enrolled. Eleven patients (28%; 95% confidence interval [CI], 15-44%) achieved a partial response. The median progression-free survival, median overall survival, and 1-year survival rate were 4.0 months (95% CI, 3.3-6.7 months), 12.6 months (95% CI, 7.0-22.3 months), and 51% (95% CI, 33-66%), respectively. The most common grade 3 or 4 toxicity was neutropenia (38%; 95% CI, 23-54%) and the rate of grade 3 or 4 nonhematologic toxicity remained at less than 5%. A multivariate Cox model showed that adenocarcinoma, nonsmoking history, and good performance status predicted better survival. CONCLUSIONS Combination chemotherapy with UFT and gemcitabine showed a promising effectiveness and acceptable toxicity for patients with platinum-resistant NSCLC.
Collapse
|
25
|
Abstract
After failure of first-line chemotherapy for advanced non-small cell lung cancer, many patients remain candidates to receive further antitumor treatment. To guide clinical management of these patients and to suggest priorities for clinical research, an International Panel of Experts met in Naples (Italy) in April 2007. Results and evidence-based conclusions are presented in this article. Single-agent chemotherapy with docetaxel or pemetrexed is the recommended option for unselected patients with performance status 0 to 2 who are candidates for second-line chemotherapy for advanced non-small cell lung cancer. Docetaxel has demonstrated superiority compared with best supportive care. Pemetrexed has been shown to be noninferior to docetaxel, with a more favorable toxicity profile. Erlotinib is effective in pretreated patients, and can be given second-line in patients not suitable or intolerant to chemotherapy, and in all patients as third-line treatment after failure of second-line chemotherapy. Gefitinib failed to show superiority to placebo as second- or third-line treatment, but it has been shown to be noninferior to docetaxel. In selected patients such as lifetime nonsmokers or those of East-Asian ethnicity, erlotinib, or gefitinib (where licensed) may be considered as second-line treatment even if they are fit for chemotherapy. Best supportive care in addition to active treatment remains important for all patients, but may be the exclusive option for patients unsuitable for more aggressive therapy. Further research is mandatory, to find better treatments, and to identify clinical and molecular predictive markers of efficacy, both for chemotherapy and for novel biologic agents.
Collapse
|
26
|
Pat K, Dooms C, Vansteenkiste J. Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: how CONSORTed are the data? Lung Cancer 2008; 62:126-38. [PMID: 18395928 DOI: 10.1016/j.lungcan.2008.02.018] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2007] [Revised: 02/20/2008] [Accepted: 02/24/2008] [Indexed: 11/28/2022]
Abstract
BACKGROUND The effect of chemotherapy on survival of patients with advanced NSCLC is modest, therefore patient reported outcomes (PRO's) are of high interest in randomized controlled trials (RCTs). CONSORT (CONsolidated Standards On Reporting Trials) is a quality checklist of 22 items for the conduct and reporting of RCTs. The aim of this report was to analyse to what extent the different RCTs with information on PRO's adhere to the CONSORT statement. METHODS Systematic review of RCTs using PRO's either as primary or secondary endpoint. Compliance with the (revised) CONSORT statement was checked by 2 independent reviewers by making for each study the simple sum of the 22 CONSORT items, or a weighted score with a maximum rating of 31 points. RESULTS The median weighted CONSORT score of the different RCTs was 25, with a remarkable difference from 12 till 30. There was no significant change over time, nor difference between academic and commercial studies, but a significant correlation between CONSORT agreement and journal type (P<0.0001). Adherence to CONSORT was similar for studies comparing chemotherapy with best supportive care alone, comparing different first-line chemotherapies with PRO either as primary or secondary endpoint, or studies looking at second-line chemotherapy. Benefit in PRO's was reported in all of these settings. CONCLUSION The overall adherence of peer-reviewed RCTs to CONSORT is reasonable, with nonetheless major differences between journals, and with no clear sign of change over time. Apart from modest survival differences, benefits in PRO endpoints are present in all categories of studies we analysed.
Collapse
Affiliation(s)
- Karin Pat
- Respiratory Oncology Unit (Department of Pulmonology) and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Leuven, Belgium
| | | | | |
Collapse
|
27
|
Breton JL, Robinet G, Dansin E, Rotarski M, Le Groumellec A, Dourthe LM, Hamid A, Ecstein-Fraisse E. [Management of non-small cell lung carcinoma following docetaxel-cisplatin. Results of an epidemiologic survey]. Rev Mal Respir 2008; 24:1099-106. [PMID: 18176386 DOI: 10.1016/s0761-8425(07)74259-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The purpose of this epidemiologic survey was to describe the management of second-line therapy for patients with stage IIIB-IV non-small cell lung carcinoma (NSCLC) following docetaxel-cisplatin as first-line therapy. METHODS Between June 2003 and December 2004, 265 patients were enrolled. The data registered were the choice of cytotoxics, the safety profile, the efficacy and the clinical benefit. RESULTS Two hundred and sixty one patients were treated with docetaxel-cisplatin as a first-line regimen and 181 received a second line. This second line was a single agent regimen in 58% of cases and a gemcitabine based treatment in 60.8%. The main criterion for the choice of second-line therapy was the safety profile in 34.3% of cases. The overall response rate was 16.6% after the second line and clinical benefit was reported in 43.6% of patients. CONCLUSION In more than 2/3 of patients with NSCLC the docetaxel-cisplatin combination leaves the opportunity to give a second-line treatment, providing satisfying results in terms of clinical benefit. In this study gemcitabine was the most widely prescribed second-line treatment, mainly as a single agent.
Collapse
|
28
|
Vázquez S, Huidobro G, Amenedo M, Fírvida JL, León L, Lázaro M, Grande C, Mel JR, Ramos M, Salgado M, Casal J. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02). Anticancer Drugs 2007; 18:1201-6. [PMID: 17893521 DOI: 10.1097/cad.0b013e328273bbce] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
The current report aims to evaluate the efficacy and safety profile of a biweekly administration of docetaxel and vinorelbine to patients with advanced non-small cell lung cancer, who had previously been treated for this disease. In a prospective, multicenter, open-label, phase II trial, patients received 40 mg/m of docetaxel and 20 mg/m of vinorelbine on days 1 and 15, every 28 days. Treatment continued for up to a maximum of six cycles, unless disease progression or unacceptable toxicity occurred, or consent was withdrawn. Fifty patients were enrolled in the study and they received 174 cycles of chemotherapy, with a median of three cycles per patient. All patients were evaluated for efficacy and toxicity in an intention-to-treat analysis. The overall response rate was 10% [95% confidence interval (CI): 1-19], including one complete response (2%) and four partial responses (8%). Previous chemotherapy of 80% of the responders included paclitaxel. Median time to disease progression was 2.7 months (95% CI: 2.2-4.3) and median overall survival was 6.5 months (95% CI: 2.5-9.2). The survival rates at 1 and 2 years were 18% (95% CI: 7-29) and 4% (95% CI: 0-10), respectively. The most frequent severe toxicities were neutropenia (20% of patients) and leukopenia (8% of patients). Other toxicities appeared in 4% or fewer of the patients. Biweekly administration of docetaxel and vinorelbine is feasible as a second-line treatment for non-small cell lung cancer patients, but its level of activity and toxicity does not suggest any advantage compared with the results obtained with single-agent docetaxel in the same setting.
Collapse
|
29
|
Takiguchi Y, Moriya T, Asaka-Amano Y, Kawashima T, Kurosu K, Tada Y, Nagao K, Kuriyama T. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer. Lung Cancer 2007; 58:253-9. [PMID: 17658654 DOI: 10.1016/j.lungcan.2007.06.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2007] [Revised: 06/04/2007] [Accepted: 06/11/2007] [Indexed: 11/20/2022]
Abstract
Even with the standard first-line chemotherapy, advanced non-small cell lung cancer (NSCLC) recurs in most cases. The purpose of this study is to develop a new chemotherapeutic regimen for patients with NSCLC that has relapsed or was refractory to previous chemotherapy. Patients with proven NSCLC refractory or recurrent after previous single-regimen chemotherapy, PS of 0-2, age of 15 years or older, adequate organ functions and measurable lesions were treated with irinotecan at 60 mg/m(2) and cisplatin at 25 mg/m(2) with 1000 ml hydration on day 1. This administration, considered as one cycle, was repeated every week without rest unless encountering defined skip and dose-reduction criteria. The treatment was administered for six cycles over a 49-day period, both median values, to 48 patients, with a response rate of 26%, progression free and median survival times of 3 and 11 months, respectively, and a 1-year survival rate of 46%. The most frequent grade 3 or 4 toxicities were neutropenia, anaemia and nausea, which were manageable. Subset analyses suggested that the response rate was independent of response to the first-line chemotherapy. In conclusion, second-line chemotherapy of weekly irinotecan and cisplatin with minimum hydration seemed effective, with tolerable toxicity, and is potentially useful irrespective of the outcome of previous chemotherapy.
Collapse
Affiliation(s)
- Yuichi Takiguchi
- Department of Respirology (B2), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Hoang T, Kim K, Merchant J, Traynor AM, McGovern J, Oettel KR, Sanchez FA, Ahuja HG, Hensing TA, Larson M, Schiller JH. Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2007; 1:218-25. [PMID: 17409860 DOI: 10.1016/s1556-0864(15)31571-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND The study was designed to evaluate the safety and efficacy of exisulind, a selective apoptotic antineoplastic drug, in combination with gemcitabine as second-line therapy in patients with progressing advanced non-small cell lung cancer. METHODS Patients whose disease progressed more than 3 months from completion of first-line chemotherapy were eligible for this phase I/II trial. Primary end points were maximally tolerated dose and time to progression. Patients in the phase I portion of the study were treated with gemcitabine (1250 mg/m) in combination with three escalated dose levels of exisulind. Treatment involved six cycles of gemcitabine and exisulind followed by exisulind maintenance. The study was subsequently expanded to phase II. RESULTS Thirty-nine patients (15 in phase I and 24 in phase II) were treated. The regimen was well tolerated with grade 3 fatigue and grade 3 constipation being dose-limiting toxicities. The maximally tolerated dose was not reached. Dose level 3 of exisulind (250 mg twice daily) in combination with gemcitabine was used for phase II. The overall response rates were 7% (phase I), 17% (phase II), and 13% (all). Median time to progression and median and 1-year survival, respectively, were 3.7 and 9.7 months and 33% (phase I); 4.3 and 9.4 months and 41% (phase II); and 4.1 and 9.4 months and 39% (all). CONCLUSION Although the study met its primary end point of improving time to progression (more than 4.1 months in phase II), we did not observe a clear survival advantage and thus do not plan to further investigate this schedule of gemcitabine and exisulind.
Collapse
Affiliation(s)
- Tien Hoang
- Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Choong NW, Mauer AM, Hoffman PC, Rudin CM, Winegarden JD, Villano JL, Kozloff M, Wade JL, Sciortino DF, Szeto L, Vokes EE. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 2007; 1:245-51. [PMID: 17409864 DOI: 10.1016/s1556-0864(15)31575-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND This study was performed to evaluate the tolerability and efficacy of temozolomide and irinotecan as a second-line regimen in recurrent/metastatic non-small cell lung cancer (NSCLC). METHODS Patients with recurrent/metastatic NSCLC, including those with treated brain metastases, following one prior platinum-based regimen received temozolomide 75 mg/m daily on days 1 through 15 and irinotecan 100 mg/m on days 8 and 15 every 21 days. RESULTS The authors treated 46 patients, of whom more that 90% had a performance status of 0 or 1. Four patients (8.7%) attained partial response and 17 (37.0%) had disease stabilization as their best response. The median time to progression was 1.8 months, median overall survival was 9.8 months, and 1-year overall survival was 34%. Grade 1/2 fatigue (63%), anemia (61%), nausea (52%), and diarrhea (44%) were the most common toxicities. Grade 3/4 leukopenia and diarrhea were each observed in 9% of patients. One unexpected death occurred, possibly related to the regimen. CONCLUSION Second-line treatment with temozolomide and irinotecan showed tolerable toxicities. The response rates, median survival times, and 1-year survival rates were comparable to other active NSCLC agents.
Collapse
Affiliation(s)
- Nicholas W Choong
- Section of Hematology-Oncology and Phase II Network, University of Chicago Medical Center, Chicago, Illinois 60615, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Cobo M, Gutiérrez V, Alcaide J, Alés I, Villar E, Gil S, Durán G, Martínez J, Carabantes F, Bretón JJ, Benavides M. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status. Lung Cancer 2007; 56:255-62. [PMID: 17276537 DOI: 10.1016/j.lungcan.2006.12.013] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2006] [Revised: 12/13/2006] [Accepted: 12/18/2006] [Indexed: 11/25/2022]
Abstract
OBJECTIVE We conducted a phase II trial to evaluate the efficacy and toxicity of a combination consisting of second-line docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy. PATIENTS AND METHODS ELIGIBILITY CRITERIA histologically confirmed advanced NSCLC with progressive disease to platinum-based chemotherapy, ECOG performance status (PS) 0 or 1, and adequate kidney, liver and bone marrow function. Treatment consisted of docetaxel 36 mg/m(2) i.v. over 60 min followed by gemcitabine 1000 mg/m(2) i.v. over 30 min on days 1 and 8 of each 3-week cycle for a planned six cycles or unacceptable toxicity. RESULTS Of the 52 patients enrolled, 50 were evaluable for response and toxicity. The mean age was 59 years (range 42-79), 46 male and 4 female. Histology subtypes were: adenocarcinoma 26 patients, bronchioloalveolar 1 patient, large cell carcinoma 5 patients, and squamous cell carcinoma 18 patients. Thirty-eight patients had ECOG PS 1 and 12 patients had PS 0. The median number of cycles administered was four (range 2-6). The overall response rate was 28%. The median follow-up was 9 months (range 5-34 months). The median survival time (MST) was 8.2 months (95% CI, 4-12%), and the 1-year survival was 25%. The median progression-free survival was 4.4 months (95% CI, 2-6%). In the Cox regression model, survival was only significantly affected by the PS. The median survival in patients with PS 0 was 17.8 months (95% CI, 18.8-21.8%) compared with a median survival for patients with PS 1 of 6.1 months (95% CI, 4.1-8.2%) (P=0.0057). TOXICITY three patients had grade 3 anemia, three patients had grade 3 thrombocytopenia, four patients had grade 3 neutropenia and only one patient developed grade 4 febrile neutropenia. Non-hematologic toxicity was also mild; the most frequent was asthenia, with grade 3 in eight patients (16%), and one patient with grade 4. CONCLUSION This regimen of docetaxel in combination with gemcitabine in advanced second-line NSCLC is an active and safe regimen.
Collapse
Affiliation(s)
- Manuel Cobo
- Medical Oncology Section, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Mori K, Kamiyama Y, Kondo T, Kano Y, Kodama T. Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy. Cancer Chemother Pharmacol 2006; 60:189-95. [PMID: 17096163 DOI: 10.1007/s00280-006-0360-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2006] [Accepted: 09/14/2006] [Indexed: 11/30/2022]
Abstract
PURPOSE We evaluated the tolerability and activity of the combination of weekly paclitaxel (PTX) and gemcitabine (GEM) in second-line treatment of advanced non-small cell lung cancer (NSCLC) after treatment with platinum-based chemotherapy. PATIENTS AND METHODS PTX (100 mg/m(2)) and GEM (1,000 mg/m(2)) were administered to patients with previous treated NSCLC on days 1 and 8 every 3 weeks. RESULTS A total of 40 patients (performance status 0/1/2, 7/27/6 pts) were enrolled. The response rate was 32.5% (95% confidence interval: 18.0-47.0%). The median survival time was 41.7 weeks (95% confidence interval: 28.5-54.7 weeks). The median time to disease progression was 19 weeks. Hematological toxicities (grade 3 or 4) observed included neutropenia in 60%, anemia in 15%, and thrombocytopenia in 12.5% of patients. Non-hematological toxicities were mild, with the exception of grade 3 diarrhea, pneumonitis, and rash in one patient each. There were no deaths due to toxicity. CONCLUSION The combination of weekly PTX and GEM is a feasible, well-tolerated, and active means of second-line treatment of advanced NSCLC.
Collapse
Affiliation(s)
- Kiyoshi Mori
- Department of Thoracic Diseases, Tochigi Cancer Center, 4-9-13, Yonan, Utsunomiya, Tochigi 320-0834, Japan.
| | | | | | | | | |
Collapse
|
34
|
Lilenbaum R, Socinski MA, Altorki NK, Hart LL, Keresztes RS, Hariharan S, Morrison ME, Fayyad R, Bonomi P. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 2006; 24:4825-32. [PMID: 17050867 DOI: 10.1200/jco.2006.07.4773] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
PURPOSE Trials combining irinotecan/docetaxel and irinotecan/gemcitabine in second-line treatment of non-small-cell lung cancer (NSCLC) have yielded promising results. Preliminary data suggested that the selective cyclooxygenase -2 inhibitor celecoxib (CBX) might enhance efficacy of chemotherapeutic regimens. This multicenter, phase II, randomized trial investigated efficacy and safety of irinotecan and docetaxel and irinotecan and gemcitabine, with or without CBX, in second-line treatment of NSCLC. PATIENTS AND METHODS Patients 18 years or older were randomly assigned to receive irinotecan 60 mg/m2 and docetaxel 35 mg/m2, or irinotecan 100 mg/m2 and gemcitabine 1,000 mg/m2, with or without CBX 400 mg twice daily, for four cycles. Primary efficacy end points were median and 1-year survival probabilities. Patient-reported symptoms were assessed by the Lung Cancer Symptoms Scale (LCSS). RESULTS A total of 133 patients were assessable for efficacy and safety. Median survival time was 6.31 months for patients treated with CBX and 8.99 months for those treated with chemotherapy alone. One-year survival rates were 24% and 36% respectively. The overall toxicity rates and LCSS scores were similar between patients treated or not treated with CBX. Four deaths were considered possibly treatment related. CONCLUSION Survival results for the second-line regimens in this study were similar to results reported for single-agent therapy in this setting. CBX did not appear to enhance efficacy or improve patient-reported symptoms. The addition of high-dose CBX to second-line chemotherapy in NSCLC cannot be recommended.
Collapse
|
35
|
Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. J Thorac Oncol 2006. [DOI: 10.1097/01243894-200611000-00021] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Noble J, Ellis P, Mackay J, Evans W. Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. J Thorac Oncol 2006. [DOI: 10.1016/s1556-0864(15)31641-5] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
|
38
|
Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer? J Thorac Oncol 2006. [DOI: 10.1097/01243894-200609000-00014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
39
|
Kurata T, Matsuo K, Takada M, Kawahara M, Tsuji M, Matsubara Y, Otani N, Matsuyama S, Muraishi K, Fujita T, Ishikawa M, Koyano K, Okamoto I, Satoh T, Tamura K, Nakagawa K, Fukuoka M. Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer? J Thorac Oncol 2006. [DOI: 10.1016/s1556-0864(15)30382-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
40
|
Hatzidaki D, Agelaki S, Mavroudis D, Vlachonikolis I, Alegakis A, Georgoulias V. A Retrospective Analysis of Second-Line Chemotherapy or Best Supportive Care in Patients with Advanced-Stage Non–Small-Cell Lung Cancer. Clin Lung Cancer 2006; 8:49-55. [PMID: 16870046 DOI: 10.3816/clc.2006.n.033] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND We retrospectively evaluated the clinical characteristics and outcome of patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) enrolled in first-line chemotherapy trials conducted by our group with respect to receiving or not receiving subsequent treatment. PATIENTS AND METHODS Data were collected from 634 patients with stage IIIB/IV NSCLC treated with platinum and nonplatinum agent-based first-line regimens. Patient survival was calculated from the day of registration to first-line chemotherapy trials (OS1) as well as from the day of first-line treatment failure or the initiation of second-line chemotherapy (OS2) until death. The decision for administering second-line chemotherapy was, in all cases, at the discretion of the physician. Two hundred twenty-four patients (35.3%) received second-line chemotherapy (second-line group) in the context of second-line clinical trials run by the same group, and 410 (64.7%) received best supportive care (BSC group). There were significant differences between second-line and BSC groups in terms of age, histology, early discontinuation of first-line chemotherapy, and performance status after first-line treatment. RESULTS Three (1.3%) complete and 25 (11.2%) partial responses to second-line chemotherapy were observed for an overall response rate of 12.5% (95% confidence interval, 8.2%-16.8%). The median OS1 was 13 months and 7 months (P < 0.001) and the OS2, 7 months and 3 months (P < 0.001) for the second-line and BSC groups, respectively. Multivariate analysis revealed that good performance status, disease stage IIIB, response to first-line treatment, and late termination of first-line chemotherapy were significantly associated with increased survival. The administration of second-line chemotherapy was also independently correlated with better outcome. CONCLUSION The second-line chemotherapy and BSC groups represent different populations of patients with NSCLC. Factors indicative of increased probability of survival could be used to identify the subgroup of patients most likely to benefit from second-line chemotherapy.
Collapse
Affiliation(s)
- Dora Hatzidaki
- Department of Medical Oncology, University General Hospital of Heraklion, Greece
| | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Makrantonakis P, Ziotopoulos P, Agelidou A, Polyzos A, Ziras A, Chandrinos V, Vossos A, Kalykaki A, Androulakis N, Geroyianni A, Georgoulias V. Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study. Lung Cancer 2006; 53:85-90. [PMID: 16720058 DOI: 10.1016/j.lungcan.2006.02.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2005] [Revised: 02/16/2006] [Accepted: 02/26/2006] [Indexed: 11/17/2022]
Abstract
PURPOSE To assess the efficacy and tolerance of the vinorelbine/cisplatin combination in non-small cell lung cancer patients pre-treated with a taxane-based regimen. PATIENTS AND METHODS Among the 32 enrolled patients, 28 (87.5%) had a PS (WHO) of 0-1 and 13 (40.6%) have previously received both platinum compounds and taxanes. Vinorelbine (25 mg/m2 on days 1 and 8) was given by a rapid i.v. infusion and cisplatin (80 mg/m2 on day 8) after appropriate hydration. The treatment was repeated every 3 weeks. RESULTS A partial response was achieved in six patients (ORR=18.8%; 95% confidence interval: 5.23-32.27); 13 (44.8%) and 10 (34.5%) patients had stable and progressive disease, respectively (intention-to-treat analysis). Four partial responses were observed in patients who were previously treated with taxanes/platinum-containing regimens. The median time to tumor progression was 4.7 months (range, 1.3-15.4). After a median follow-up period of 6.3 months (range, 1.3-15.4) the median overall survival was 7.6 months and the 1-year survival rate 17.7%. Grade 3 and 4 granulocytopenia was observed in 11 (34.4%) patients and grade 4 thrombocytopenia in one (3.1%). Eleven (34.4%) patients presented grade 2 and 3 anemia. Febrile neutropenia occurred in one (3.1%) patient. Grade 3 and 4 nausea/vomiting was reported in one (9.3%) patient each and grade 2 fatigue in four (12.5%). CONCLUSIONS The combination of vinorelbine and cisplatin is an active and well tolerated salvage regimen in NSCLC patients pre-treated with taxane-based chemotherapy.
Collapse
Affiliation(s)
- P Makrantonakis
- Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, 71100 Heraklion, Crete, Greece
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP. A phase I–II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol 2006; 59:51-9. [PMID: 16622691 DOI: 10.1007/s00280-006-0242-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2005] [Accepted: 03/24/2006] [Indexed: 10/24/2022]
Abstract
PURPOSE Treatment options in patients with recurrent non-small cell lung cancer (NSCLC) remain limited as a result of poor activity of most agents after failure of platinum-based therapy. In the present phase I-II study, we evaluated the feasibility and efficacy of bi-weekly gemcitabine (GEM) + irinotecan (CPT-11) in patients with relapsed NSCLC. PATIENTS AND METHODS Patients with advanced NSCLC, WHO-performance status (PS) </= 2, prior taxane/platinum-based chemotherapy were eligible. Chemotherapy was administered in a dose-escalated fashion in subgroups of 3-6 patients until dose-limiting toxicity (DLT) was encountered as follows: CPT-11 150 or 180 mg/m(2) followed by GEM 1,200-1,800 mg/m(2), both on days 1 + 15, recycled every 28 days in four dose levels (DLs). RESULTS Forty-nine patients entered the phase I and II part of the study (phase I: 12-phase II: 37 + 3 at DL-3), and 40 patients were evaluable for a response in phase II and all for toxicity: median age, 61 years (range 36-74); PS, 1 (0-2); gender, 43 males/6 females-histologies; adenocarcinoma, 25; squamous, 20; large cell, 4. Metastatic sites included lymph nodes, 38; bone, 5; liver, 4; brain, 3; lung nodules, 14; adrenals, 13; other, 3. All patients had prior taxane + platinum-based treatment, and 42 patients had prior docetaxel-ifosfamide-cisplatin/or-carboplatin regimens. DLT was observed at DL-4 and included 2/3 cases with grade 3 diarrhea-1/3 of these with febrile neutropenia. The recommended DL for phase II evaluation was DL3: GEM, 1,500 + CPT-11-180 mg/m(2). Objective responses in phase II were PR, 6/40 [15%; 95% confidence interval (CI), 5-31%]; stable disease, 16/40 (40%; 95% CI, 21-53%); and progressive disease, 18/40 (45%; 95% CI, 28.5-62.5%). The median time-to-progression was 4 months (range 1-12) and median survival 7 months (range 1.5-42 +), while 1-year survival was 20%. Grade 3/4 neutropenia was seen in 18% of patients (6% grade 4) and 6% incidence of febrile neutropenia. No Grade 3/4 thrombocytopenia were seen, grade 3 diarrhea in 6% of patients and grade 2 in 15% of patients, while other grade 3 non-hematologic toxicities were never encountered. CONCLUSIONS Bi-weekly GEM + CPT-11 is active and well tolerated in patients with advanced NSCLC failing prior taxane + platinum regimens, and represents an effective and convenient combination to apply in the palliative treatment of relapsed NSCLC particularly after failure of first-line docetaxel + platinum-based regimens.
Collapse
Affiliation(s)
- Christos Kosmas
- Second Division of Medical Oncology, Department of Medicine, "Metaxa" Cancer Hospital, Piraues, 21 Apolloniou Street, 16341, Athens, Greece.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Feliu J, Martín G, Castro J, Sundlov A, Rodriguez-Jaráiz A, Casado E, Lomas M, Madroñal C, Galán A, Belda C, Gonzalez-Barón M. Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2006; 58:527-31. [PMID: 16555090 DOI: 10.1007/s00280-006-0198-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2005] [Accepted: 01/24/2006] [Indexed: 10/24/2022]
Abstract
PURPOSE To evaluate the feasibility, toxicity and efficacy of the combination of docetaxel and mitomycin C as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Thirty-eight patients with histologically confirmed, locally advanced or metastatic NSCLC were included in this phase II trial. All patients had been previously treated with a platinum-based regimen. Treatment consisted of docetaxel (75 mg/m2) followed by mitomycin C (8 mg/m2) on day 1, every 21 days. Patients received a minimum of three courses unless progressive disease was detected. RESULTS A total of 190 courses of docetaxel-mitomycin C were administered (median five courses per patient). This combination was well tolerated with grade 3-4 toxicity experienced with the following frequency: neutropenia in five patients (13%), fatigue in four (11%), anaemia, thrombocytopenia, nausea/vomiting and peripheral neuropathy in one each (3%). Three of 38 patients had a partial response (8%, 95% confidence interval 2.6-21.6%), 14 patients (37%) experienced stabilization of disease and 21 (55%) had disease progression. Median time to progression was 3.6 months. Overall median survival was 10.4 months, with the 1-year actuarial survival rate being 35%. CONCLUSIONS The addition of mitomycin C to docetaxel as second-line therapy in NSCLC is well tolerated but does not seem to improve the response rate.
Collapse
Affiliation(s)
- J Feliu
- Servicio de Oncología Médica, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Barlési F, Jacot W, Astoul P, Pujol JL. Second-line treatment for advanced non-small cell lung cancer: A systematic review. Lung Cancer 2006; 51:159-72. [PMID: 16360238 DOI: 10.1016/j.lungcan.2005.08.017] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2005] [Accepted: 08/17/2005] [Indexed: 01/19/2023]
Abstract
BACKGROUND Among advanced non-small cell lung cancer (NSCLC) patients, most will resist or relapse after first-line chemotherapy. As a result, second-line therapy has been a major focus for clinical research. MATERIALS AND METHODS A systematic review was carried out from 1996 to February 2005. RESULTS Second-line chemotherapy provides pre-treated NSCLC patients with a clear survival advantage. Docetaxel 75 mg/m(2) every 3 weeks is the present standard second-line chemotherapy. Despite promising results regarding efficacy and toxicity in phase III studies, a docetaxel weekly schedule could not be recommended. Pemetrexed recently emerged as an alternative with similar efficacy and less toxicity. Although the combination of two drugs was not associated with a survival benefit when compared with single-agent chemotherapy, such regimens induced a dramatic increase in toxicities and therefore mono-chemotherapy remains the standard as second-line therapy. Finally, few new agents were reported with better results than those used previously and clinical research on second-line therapy currently focuses on combinations with targeted therapies. CONCLUSION Second-line chemotherapy offers NSCLC patients a small but significant survival improvement. However, this field of clinical research needs further investigations in order to answer certain remaining questions especially concerning targeted therapies.
Collapse
Affiliation(s)
- Fabrice Barlési
- Faculty of Medicine, Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Thoracic Oncology, Fédération des Maladies Respiratoires, Sainte-Marguerite Hospital, France.
| | | | | | | |
Collapse
|
46
|
Abstract
Slow but steady progress has been made in the treatment of advanced non-small cell lung cancer. For first-line therapy, multiple chemotherapy combination therapies can extend survival and improve quality of life. And recently, for the first time ever, a noncytotoxic agent, the antivascular endothelial growth factor antibody bevacizumab, has been shown to improve survival when added to chemotherapy. Striking improvements have also been made in second-line treatment. In August 2004, only one agent was US Food and Drug Administration (FDA) approved in this setting, docetaxel, but by the beginning of 2005, two more were available, pemetrexed and erlotinib. All three of these drugs can significantly benefit patients, with 1-year survival in excess of 30%. Choosing between the three agents can be challenging, and this review focuses on the toxicity differences and predictors of response that can help guide this decision. Docetaxel and pemetrexed, both traditional intravenous cytotoxins, are excellent options for patients who have shown some response to first-line chemotherapy, but at this time, no other means exist to determine likelihood of response. When choosing between the two, pemetrexed causes significantly less neutropenia than does docetaxel, at least on the standard every-3-week regimen. With erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, there are factors that can predict for response, including little or no smoking history, and adenocarcinoma histology. Therefore, patients who fit these characteristics are good candidates for second-line erlotinib. However, the relationship between response to erlotinib and improved survival remains unclear, and several laboratory analyses that may help further, such as evaluation of EGFR gene copy number, are still under development. Although erlotinib is the only FDA-approved option currently available for third-line therapy, many patients with good performance status may benefit from third-line therapy and beyond. In addition to the approved second-line options, other single-agent chemotherapies to consider for treatment beyond second-line are gemcitabine, irinotecan, and oral topotecan. Many new drugs, including bevacizumab, ZD6474 (AstraZeneca, Wilmington, DE), sorafenib, cetuximab, paclitaxel poliglumex, epothilones, and others, alone or in combination with traditional agents, are currently undergoing investigation and hold great promise.
Collapse
Affiliation(s)
- Atul Kumar
- Stanford Cancer Center, Stanford, CA 94305, USA.
| | | |
Collapse
|
47
|
de Marinis F, De Santis S, De Petris L. Second-Line Treatment Options in Non–Small Cell Lung Cancer: A Comparison of Cytotoxic Agents and Targeted Therapies. Semin Oncol 2006; 33:S17-24. [PMID: 16472705 DOI: 10.1053/j.seminoncol.2005.12.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Current options for the second-line treatment of non-small cell lung cancer (NSCLC) include cytotoxic drugs, such as docetaxel and pemetrexed, and targeted therapies. Docetaxel was approved in the United States and Europe in 2000 after two phase III trials showed drug superiority versus best supportive care alone and versus alternative single-agent chemotherapy. Pemetrexed was approved in the United States and Europe in 2004 after a phase III trial showed that, compared with docetaxel, it had comparable activity (median survival time of approximately 8 months in both arms) and a more favorable toxicity profile: grade 3-4 neutropenia was observed in 5.3% versus 40.2% of patients in the pemetrexed and docetaxel arms, respectively, while febrile neutropenia was observed in 1.9% versus 12.7% of patients, respectively. In the United States, gefitinib and erlotinib have also been approved for the treatment of recurrent NSCLC (in 2003 and 2004, respectively), while in Europe the registration of these agents is currently under evaluation. This review focuses on the use of docetaxel and pemetrexed for the second-line treatment of NSCLC and compares these drugs with targeted therapies, highlighting the latest developments in pharmacogenomics that might lead to a more tailored approach to treatment.
Collapse
Affiliation(s)
- Filippo de Marinis
- 5th Pneumo-oncology Unit, Department of Oncology, S. Camillo-Forlanini Hospitals, Rome, Italy.
| | | | | |
Collapse
|
48
|
Georgoulias V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J, Polyzos A, Athanasiadis A, Tselepatiotis E, Androulakis N, Kalbakis K, Samonis G, Mavroudis D. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Br J Cancer 2005; 93:763-9. [PMID: 16175189 PMCID: PMC2361638 DOI: 10.1038/sj.bjc.6602748] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The aim of this study was to compare the irinotecan/cisplatin regimen with cisplatin as second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) pretreated with a taxane/gemcitabine regimen. Patients (n = 147) with stage IV NSCLC pretreated with a taxane/gemcitabine regimen were randomly assigned to receive either irinotecan (110 mg m(-2), day 1 and 100 mg m(-2), day 8) and cisplatin (80 mg m(-2), day 8) (IC; n = 74) or CDDP (80 mg m(-2), day 1) (C; n = 73) every 3 weeks. Patients treated with IC and C had a median survival of 7.8 and 8.8 months, respectively (P = 0.933). The 1-year survival rate was 34.3% for IC-treated patients and 31.7% for C-treated patients. Cox's regression analysis revealed that response to treatment (hazard ratio (HR) = 2.787; 95% confidence interval (CI): 1.1578-4.922) and performance status (HR = 1.865; 95% CI: 1.199-2.872) was independent prognostic factors for survival. Overall response rate was 22.5% (95% CI: 12.8-32.2%) for IC-treated patients and 7.0% (95% CI: 1.15-13.6%) for C-treated patients (P = 0.012); tumour growth control (partial remission (PR) + stable disease (SD)) was observed in 26 (38%) IC and 25 (36%) C patients (P = 0.878). There was no difference in terms of quality of life between the two chemotherapy arms. The incidence of febrile neutropenia, grade 3 and 4 neutropenia and grade 3 and 4 diarrhoea was significantly higher in the IC- than the C-treated patients. Other toxicities were mild. There were no treatment-related deaths in either arm. The IC regimen did not confer a survival benefit compared with C as second-line treatment of patients with advanced NSCLC pretreated with a taxane/gemcitabine regimen, despite its better efficacy in terms of response rate.
Collapse
Affiliation(s)
- V Georgoulias
- Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|